Roquefort/Lyramid postings, page-2

Ms Duvall is a highly accomplished individual in the biotech and pharma sector, with over 25 years experience in executive roles in the industry. During this time, Ms Duvall acted for Ferring Pharmaceuticals, as one of the Executive Board Members who built the company from a US$700 million to US$2 billion in revenue. During her time at Ferring, Ms Duvall led or co-led over 10 transactions and had legal oversight on over 25 transactions. Ms Duvall has a significant track record in corporate development having led multiple successful M&A, divestment and licensing deals throughout her career. During her time at Elan Corporation, Ms Duvall was responsible for the launch and commercialisation of Tysabri, a treatment for multiple sclerosis and Crohn's disease, outside of the US in collaboration with Biogen Idec. She previously had the role of General Counsel at Elan and was legal lead, negotiating the divestment of over $2bn in assets.

Additionally, she has co-founded and led biopharma start-ups including Trizell and Amzell, resulting in multiple products having successful phase 2 and 3 clinical studies. Trizell in particular received several multi-billion dollar offers for its lead oncology gene therapy product, Adstiladrin, which is now in the registration phase.

Ms Duvall is currently CEO and Co-Founder of ReproNovo, a women's health and reproductive medicine company focussing on R&D and manufacturing with potential products entering phase 2 and phase 1. Additionally, Ms Duvall is a Non Executive Board member of an AIM listed life sciences company, Ondine Biomedical Inc., a company focused on photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens.